Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaunoXome vs ABV in HIV-associated Kaposi's sarcoma
NCT00002093Phase 3Completed
- Sponsor
- NeXstar Pharmaceuticals
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daunorubicin in Kaposi's sarcoma (KS) (2 arms), sponsored by NeXstar Pharmaceuticals. Primary endpoint: Objective Response Rate. Status: completed.
02
Drugs
daunorubicin
03
Conditions
Kaposi's sarcoma (KS)
Beyond the preview
Go deeper on NCT00002093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002093.